喉癌组织Bax基因的表达及其临床相关性

Study of Bax gene in laryngeal carcinoma and it's clinical relationship

采用免疫组织化学SABC法，分别对喉癌、声带息肉及正常声带组织的Bax基因进行检测。结果显示，Bax基因免疫组织阳性反应为棕黄色颗粒，表达部位位于细胞浆内。阳性表达分别为：95例喉癌中57例（60．0％），10例声带息肉中5例（50．0％），6例正常声带腺体中5例（83．3％）。喉癌吸烟患者与不吸烟患者的Bax基因表达阳性存在显著性差异（P＜0．05）。Bax基因表达阳性者3，5，10年生存率分别为86．6％，84．1％，79．9％；阴性者3，5，10年生存率分别为77．2％，72．5％，58．0％。Bax基因表达阳性者生存曲线明显高于其防性者；死亡危险度Bax基因表达阳性者波峰低于阴性者。提示Bax基因表达对喉癌的诊断与预后的判定具有重要的应用价值。

The Bax gene in laryngeal carcinoma, vocal polyp and normal laryngeal tissue were investigated respectively by the SABC immunohistochemistry. Results showed that Bax positive products were brownish yellow granules which were located in the cytoplasm of cancer cells. The positive rate of laryngeal carcinoma, vocal polyp and normal vocal gland were 60. 0% (57/95) 、50.0% (5/10) and 83. 3% (5/6) respectively. There is a significant difference in Bax gene positive expression in laryngeal carcinoma between nonsmoking and smoking patients (P <0.05). The 3.5 and 10 years survival rates of Bax positive patients were 86. 6%, 84. 1% and 79. 9%respectively. As to the negative ones, the above rates were 77. 2%, 72. 5% and 58. 0%respectively. The survival curve in patients shown to be positive is higher than that in the negativeone, the wave crest of mortality risk in positive patient is lower than that in the negetive ones.These results indicated that Bax expression has applicable value in the diagnosis of laryngeal carcinoma and its prognosis and judgement.